Rode Kruis Ziekenhuis Beverwijk

Beverwijk, Netherlands

Rode Kruis Ziekenhuis Beverwijk

Beverwijk, Netherlands

Time filter

Source Type

Lips M.A.,Leiden University | De Groot G.H.,Rode Kruis Ziekenhuis Beverwijk | Van Klinken J.B.,Leiden University | Aarts E.,Rijnstate Ziekenhuis | And 8 more authors.
Clinical Endocrinology | Year: 2014

Objective Roux-en-Y gastric bypass (RYGB) and restrictive weight loss interventions, such as gastric banding (GB) and very-low-calorie diets (VLCD) directly impact glucose metabolism, possibly by calorie restriction and/or altered secretion of gut hormones. We aimed to establish the direct endocrine and metabolic effects of RYGB compared to restrictive interventions in obese glucose-tolerant (NGT) subjects and subjects with type 2 diabetes (T2DM). Design Controlled, nonrandomized observational trial. Patients and measurements Four groups of obese females received a mixed meal at baseline and 3 weeks after intervention; NGT-GB (n = 11), NGT-RYGB (n = 16), T2DM-RYGB (n = 15) and T2DM-VLCD (n = 12). Normal weight controls (n = 12) were studied once. Results At baseline, all obese subjects were hyperinsulinemic. T2DM was associated with hyperglycaemia and decreased GLP-1 levels. RYGB and VLCD reduced glucose levels to a similar extent in T2DM, insulin levels decreased only after VLCD. Comparison of restrictive intervention vs RYGB showed a more pronounced decrease in glucose and insulin AUC after restriction. In NGT and T2DM subjects, RYGB increased GLP-1 and PYY levels and decreased ghrelin levels, whereas VLCD and GB only increased GIP levels. Conclusions These data indicate that deterioration of glucose metabolism in T2DM is associated with a decline of GLP-1 levels. Calorie restriction facilitates glucose metabolism and blunts hyperinsulinemia in obese (diabetic) humans. Additional duodenal exclusion through RYGB induces gut hormone release and hyperinsulinemia but does not improve postprandial glucose levels any further. Our data thus strongly suggest that calorie restriction underlies the short-term metabolic benefits of RYGB in obese T2DM patients. © 2013 John Wiley & Sons Ltd.

Loading Rode Kruis Ziekenhuis Beverwijk collaborators
Loading Rode Kruis Ziekenhuis Beverwijk collaborators